SELLAS Life Sciences Group’s Phase II clinical trials of galinpepimut-S, an immunotherapeutic anti-cancer treatment, have illustrated significant benefits for those patients who have utilized it following autotransplantation with high-risk multiple myeloma, particularly those with an adverse cytogenetic profile. “We are encouraged by these positive results and planning further studies to expand upon and confirm our observations,” said Guenther Koehne, MD, PhD.
The Principal Investigator for the Phase II trial of galinpepimut-S, Guenther Koehne MD, PhD has optimistically expressed his hope that,”… immunotherapeutic strategies targeting this antigen could improve key outcomes in patients with multiple myeloma.” SELLAS Life Sciences Group Vice Chairman and CEO Dr. Angelos Stergiou affirms the positive Phase II results for acute myeloid leukemia and malignant pleural mesothelioma and prepares for Phase III trials to begin. Nicholas Sarlis, MD, PhD and SELLAS Chief Medical Officer feels that the promising statistics from a pilot clinical study in myeloid myeloma supports additional evaluation of the potential applications of galinpepimut-S in studies of patients with a poor outlook. “We are now witnessing promising responses in these high-risk patients, who typically relapse within 12-15 months of autotransplant. We are committed to more clinical research for this high unmet medical need population with our agent, aiming to understand the immunobiological mechanisms behind its positive effects,” said Dr. Sarlis.
Galinpepimut-S was developed by Sloan Kettering Cancer Center and is now licensed to SELLAS Life Sciences Group. Vice Chairman and CEO Dr. Angelos Stergiou works with the SELLAS team which is performing patient testing trials of galinpepimut-S, a late-stage cancer immunotherapy.